UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study
Apr 7 2021
UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe (LINK). With no serious adverse effects reported, the study showed a strong safety profile of inhaled and intranasal niclosamide which was the primary endpoint for the trial.
The promising safety and pharmacokinetic results for inhaled and intranasal niclosamide have opened the doors for further investigation, and will now be tested as a potential treatment (UNI91104) and prophylaxis (UNI91103) for COVID-19. Niclosamide was shown by Institut Pasteur to have a 40-fold better potency than remdesivir against SARS-CoV-2.
UNION therapeutics COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication
The Lancet Regional Health - Europe has published the results of UNION therapeutics phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104)
The study endpoints were to assess the safety profile and the pharmacokinetic profile of niclosamide when administered as a nasal spray and as an inhalation product (nebulizer)
The study was placebo-controlled and conducted in healthy volunteers
No adverse effects were identified, paving the way for further investigation in COVID-19 patients
On the basis of these results UNI91103 has been selected as the first intervention of the PROTECT-V study, which recently received UK Urgent Public Heath prioritization